Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech Inc (KRYS – Research Report), Avenue Therapeutics Inc (ATXI – Research Report) and Advaxis (ADXS – Research Report).
Krystal Biotech Inc (KRYS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech Inc, with a price target of $32. The company’s shares closed yesterday at $21.05.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $32 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our model currently received the majority of valuation contribution from KB103 for the treatment of DEB patients, with modest contribution from KB105 for ARCI. We believe potential upside exists as clinical data are delivered from both of these assets, as well as potential contribution from pipeline development.”
According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -16.6% and a 27.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech Inc with a $41.17 average price target, which is a 95.6% upside from current levels. In a report issued on March 6, Chardan Capital also reiterated a Buy rating on the stock with a $50 price target.
Avenue Therapeutics Inc (ATXI)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Avenue Therapeutics Inc today and set a price target of $11. The company’s shares closed yesterday at $5.55.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.7% and a 42.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on Avenue Therapeutics Inc is a Moderate Buy with an average price target of $11.
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Advaxis today. The company’s shares closed yesterday at $0.41, close to its 52-week low of $0.18.
“We maintain our Neutral rating of ADXS with no price target due to the significant uncertainties surrounding the company’s core ADXS-HOT programs. (1) clinical; (2) financial; (3) regulatory; (4) commercial; and (5) intellectual property.”
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.6% and a 35.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Collplant Holdings Ltd, Gritstone Oncology Inc, and Trillium Therapeutics.
Advaxis has an analyst consensus of Moderate Buy, with a price target consensus of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.